Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Suvorexant Scheduled, But DEA Delays Remain an Issue

This article was originally published in RPM Report

Executive Summary

DEA scheduled Merck’s Belsomra (suvorexant) August 28, only two weeks after its August 13 approval – much faster than the year-long wait for some drugs. But don’t take that to mean that the DEA process is moving faster for new drugs.

Advertisement

Related Content

DEA Delays in Scheduling Are Offsetting FDA’s Improved Decision Making

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079753

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel